AstraZeneca Commits $15 Billion To China In Major Expansion Plan

AstraZeneca said it will invest $15 billion in China through 2030, expanding manufacturing and research as Beijing and London seek to revive commercial ties. The announcement came during UK Prime Minister Keir Starmer’s visit to Beijing, the first by a British leader in eight years.

AstraZeneca said the funding will strengthen drug production, research, and advanced therapies, including cell therapy and radioconjugates.

Starmer said the investment would support thousands of jobs in the UK and reinforce Britain’s life sciences sector.

UK drugmaker AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, it said on Thursday as British Prime Minister Keir Starmer visited Beijing. https://t.co/72nfGGWCkk https://t.co/72nfGGWCkk

— Reuters Health (@Reuters_Health) January 29, 2026

During the visit, Chinese President Xi Jinping called for closer cooperation and a new phase in UK-China relations, according to state media.

China is AstraZeneca’s second-largest market and a growing research hub. Analysts say the investment reflects China’s rising role in global pharmaceutical innovation.

Also read:

Why China Is Moving To Curb AI Job Displacement Risks

China is moving to address job displacement risks linked to artificial intelligence as automation expands across major industries. The Ministry of Human Resources and Social Security said it will release a policy document later this year outlining measures to manage AI’s impact on employment. The announcement follows rapid advances

tippinsightsTIPP Staff